The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
The FDA to review Vyxeos New Drug Application for AML
On 3rd April 2017, a New Drug Application (NDA) for vyxeos (CPX-351), a liposomal formulation of cytarabine plus daunorubicin co-encapsulated at a molar ratio of 5:1, was submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with Acute Myeloid Leukemia (AML).1
The NDA submission was based on clinical data from five studies including a pivotal phase III study (NCT01696084), which was presented at the American Society of Clinical Oncology meeting 2016 by Jeffrey E. Lancet from the Lee Moffitt Cancer Center & Research Institute, Florida, USA, and colleagues.2
In this phase III study, 309 newly diagnosed AML patients (60–75 years) were randomized to receive either CPX-351 (n = 153) or 7+3 (cytarabine and daunorubicin, n = 156) induction therapy. The endpoints of the study were Overall Survival (OS), Event Free Survival (EFS), and Complete Remission plus Complete Remission with Incomplete blood count recovery (CR+CRi).
The key results of the study were:
- Median OS in patients receiving CPX-351 and 7+3; 9.56 vs 5.95 months, HR = 0.69, P = 0.005
- EFS was superior in patients receiving CPX-351 compared to 7+3; HR = 0.74, P = 0.021
- CR+CRi response in patients receiving CPX-351 and 7+3; 47.7% vs 33.3%, P = 0.016
In summation, CPX-351 improved the survival in older patients with AML. Currently, CPX-351 is being investigated in a multiple study in newly diagnosed and relapsed/refractory AML patients.
References